Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Here's What Happened

Key Points

• Capricor shares fell 4.5% to $28.675 on Tuesday (intraday low $28.59) on just 176,375 shares traded, about a 92% drop versus its average session volume, after closing at $30.04 the prior day.
• Wall Street sentiment is broadly bullish with multiple upgraded price targets (Oppenheimer $54, UBS $50, B. Riley $50, Piper Sandler $45), leaving a consensus rating of “Moderate Buy” and an average price target of $40.82.
• Fundamentals: Capricor is a clinical‑stage biotech (market cap ~$1.33B, negative P/E) developing CAP‑1002 for DMD and COVID‑19 heart injury and reported quarterly EPS of ($0.54), in line with estimates.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) fell 4.5% on Tuesday . The company traded as low as $28.59 and last traded at $28.6750. 176,375 shares traded hands during trading, a decline of 92% from the average session volume of 2,123,972 shares. The stock had previously closed at $30.04.

Wall Street Analyst Weigh In

CAPR has been the subject of a number of recent research reports. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a report on Monday, December 15th. Piper Sandler reaffirmed an "overweight" rating and issued a $45.00 price objective (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Oppenheimer increased their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an "outperform" rating in a research report on Monday, December 8th. B. Riley restated a "buy" rating and issued a $50.00 target price (up from $21.00) on shares of Capricor Therapeutics in a research note on Monday, December 15th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $40.82.

Capricor Therapeutics Trading Down 3.3%

The company has a market cap of $1.33 billion, a PE ratio of -16.07 and a beta of 0.62. The firm's 50-day simple moving average is $14.25 and its two-hundred day simple moving average is $10.04.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.54). As a group, analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Trading of Capricor Therapeutics

Several large investors have recently made changes to their positions in CAPR. Voleon Capital Management LP acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $311,000. Moneta Group Investment Advisors LLC grew its stake in Capricor Therapeutics by 25.5% in the 3rd quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company's stock valued at $248,000 after acquiring an additional 7,000 shares during the period. Brevan Howard Capital Management LP purchased a new stake in Capricor Therapeutics in the 3rd quarter worth $123,000. Raymond James Financial Inc. raised its position in Capricor Therapeutics by 1,629.9% during the third quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company's stock worth $1,379,000 after acquiring an additional 180,234 shares during the period. Finally, Brooklyn Investment Group acquired a new position in Capricor Therapeutics during the third quarter worth $274,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.